Wall Street brokerages predict that InVitae Corp (NASDAQ:NVTA) will announce earnings of ($0.61) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for InVitae Corp’s earnings, with estimates ranging from ($0.65) to ($0.57). InVitae Corp reported earnings per share of ($0.77) during the same quarter last year, which would suggest a positive year over year growth rate of 20.8%. The company is expected to announce its next earnings report on Monday, August 14th.

On average, analysts expect that InVitae Corp will report full year earnings of ($2.38) per share for the current fiscal year, with EPS estimates ranging from ($2.48) to ($2.31). For the next financial year, analysts forecast that the firm will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.84) to ($1.51). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow InVitae Corp.

InVitae Corp (NASDAQ:NVTA) last released its quarterly earnings results on Tuesday, May 9th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. The business had revenue of $10.34 million during the quarter, compared to analyst estimates of $10.90 million. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. InVitae Corp’s quarterly revenue was up 161.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.80) EPS.

A number of analysts recently issued reports on the company. Benchmark Co. reiterated a “buy” rating and issued a $16.00 price target (up previously from $11.00) on shares of InVitae Corp in a report on Monday, April 3rd. ValuEngine downgraded shares of InVitae Corp from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $12.69.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/03/invitae-corp-nasdaqnvta-expected-to-announce-earnings-of-0-61-per-share-updated-updated-updated.html.

Several institutional investors have recently modified their holdings of NVTA. Donald L. Hagan LLC acquired a new position in shares of InVitae Corp during the first quarter worth about $111,000. Verity Asset Management Inc. acquired a new position in shares of InVitae Corp during the first quarter worth about $116,000. Nationwide Fund Advisors increased its position in shares of InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after buying an additional 2,987 shares during the last quarter. American International Group Inc. increased its position in shares of InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of InVitae Corp during the first quarter worth about $200,000.

InVitae Corp (NVTA) traded up 0.88% on Thursday, reaching $9.22. The company’s stock had a trading volume of 151,922 shares. The firm has a 50-day moving average of $9.21 and a 200-day moving average of $9.50. The company’s market capitalization is $390.14 million. InVitae Corp has a one year low of $5.76 and a one year high of $11.88.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Get a free copy of the Zacks research report on InVitae Corp (NVTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for InVitae Corp (NASDAQ:NVTA)

Receive News & Stock Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related stocks with our FREE daily email newsletter.